Celgene Corp (CELG)

CELG (NASDAQ:Drugs) EQUITY
$99.18
pos +0.00
+0.00%
Today's Range: 0.00 - 0.00 | CELG Avg Daily Volume: 5,887,100
Last Update: 02/08/16 - 4:00 PM EST
Volume: 0
YTD Performance: -17.18%
Open: $0.00
Previous Close: $99.18
52 Week Range: $92.98 - $140.72
Oustanding Shares: 785,654,567
Market Cap: 76,907,725,564
6-Month Chart
TheStreet Ratings Grade for CELG
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 13 13 13 12
Moderate Buy 1 1 1 1
Hold 3 2 2 2
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.41 1.31 1.31 1.33
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 20.78
Price Earnings Comparisons:
CELG Sector Avg. S&P 500
20.78 82.00 28.38
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-15.04% -16.48% 98.10%
GROWTH 12 Mo 3 Yr CAGR
Revenue 18.10 0.58 0.16
Net Income 37.90 0.52 0.15
EPS 42.00 0.72 0.20
Earnings for CELG:
EBITDA 2.94B
Revenue 7.67B
Average Earnings Estimates
Qtr (03/16) Qtr (06/16) FY (12/16) FY (12/17)
Average Estimate $1.05 $1.15 $4.75 $6.52
Number of Analysts 2 2 2 1
High Estimate $1.11 $1.20 $4.94 $6.52
Low Estimate $0.99 $1.10 $4.56 $6.52
Prior Year $0.95 $1.08 $4.08 $4.75
Growth Rate (Year over Year) 10.53% 6.48% 16.42% 37.26%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
We anticipate that price rallies in the prior support area ($105 to $110) fail and become new resistance. 
Bearish
Jan 29, 2016 | 7:13 AM EST
Shares of CELG now seen reaching $146, according to Jefferies. Estimates also reduced, given currency headwinds. Buy rating. 
Celgene, AbbVie and Gilead are set to report earnings. Here's what to look for.
We need some cooperation from China and oil. Please.
Many say you should never sell puts, but there are times when it can work.
Update
Jan 11, 2016 | 7:06 AM EST
JPMorgan Healthcare Conference (Day 1 of 5) - 01/11/16 - 01/15/16 San Francisco, CA
5 biotech stocks that could outperform the overall market in 2016.

Columnist Conversations

Keeping in mind that timing is not 100%, I have a cluster of cycles suggesting a low in GOOGL. The cycles are...
I'm not at a major downside target yet in SPX, but I do have timing for a tradable bounce in the next few trad...
What the market bloodbath reinforces: always hold a realistic view of the future (dare I say, conservative).
Kelly Services had been strong this morning in the face of intense broad-based selling overall. The stock buil...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.